

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 11, 2022

**ANEBULO PHARMACEUTICALS, INC**  
(Exact name of Registrant as Specified in Its Charter)

Delaware  
(State or Other Jurisdiction  
of Incorporation)

001-40388  
(Commission  
File Number)

85-1170950  
(IRS Employer  
Identification No.)

Anebulo Pharmaceuticals, Inc.  
1415 Ranch Road 620 South, Suite 201  
Lakeway, TX  
(Address of Principal Executive Offices)

78734  
(Zip Code)

Registrant's Telephone Number, Including Area Code: (512) 598-0931

Not Applicable  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$.0001 par value per share	ANEB	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 2.02 Results of Operations and Financial Condition.**

On May 11, 2022, Anebulo Pharmaceuticals, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter ended March 31, 2022 and providing a business update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

Exhibit Number	Description
-------------------	-------------

---

99.1	<a href="#">Press Release dated May 11, 2022</a>
104	Cover Page of Interactive Data File (embedded within the Inline XBRL document).

---

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ANEBULO PHARMACEUTICALS, INC.**

Date: May 11, 2022

By: /s/ Simon Allen  
Simon Allen  
Chief Executive Officer  
(Principal Executive Officer)

---



### Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2022 Financial Results and Recent Updates

**AUSTIN, Texas (May 11, 2022)** – Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse (the “Company” or “Anebulo”), today announced financial results for the three months ended March 31, 2022 and recent updates.

Third Quarter Fiscal Year 2022 and Subsequent Highlights:

- **Completed enrollment of all 60 subjects in Part A of an ongoing Phase 2 proof-of-concept clinical trial at the Centre for Human Drug Research (CHDR) in the Netherlands.** The Company intends to release top line data for Part A by June 30, 2022.
- **Company Executives are scheduled to participate in the following investor conferences:**
  - H.C. Wainwright Global Investment Conference, May 23-26, 2022
  - Benchmark 2022 Healthcare Housecalls IX1 Institutional Investor Conference on June 2, 2022
  - LD Micro Invitational XII Conference, June 7-9, 2022
  - 2022 BIO International Convention, June 13-16, 2022
- **A company-sponsored abstract on the antagonistic effects of ANEB-001 was accepted for a poster presentation at the 32nd Annual International Cannabinoid Research Society Symposium on the Cannabinoids, June 25-30, 2022.**

#### Management Commentary

“We are pleased to announce that Part A of our ongoing Phase 2 proof-of-concept clinical trial is now fully enrolled, keeping us on-track to release top line data before the end of this current quarter,” stated Simon Allen, Chief Executive Officer of Anebulo. “We look forward to announcing the Part A data and providing further guidance on our path to product approval.”

#### Third Quarter Fiscal 2022 Financial Results

- Operating expenses in the third quarter of fiscal 2022 were \$1.9 million compared with \$0.6 million in the same period in fiscal 2021.
- Net loss in the third quarter of fiscal 2022 was \$1.9 million, or \$(0.08) per share, compared with a net loss of \$0.6 million, or \$(0.68) per share, in the third quarter of fiscal 2021.
- Cash burn in the third quarter of fiscal 2022 was \$1.5 million.
- Cash and cash equivalents were \$16.5 million as of March 31, 2022.

#### About Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication and substance abuse. Its lead product candidate, ANEB-001, is intended to reverse the negative effects of acute cannabinoid intoxication within one hour of administration. ANEB-001 is a competitive antagonist at the human cannabinoid receptor type 1 (CB1). For further information about Anebulo, please visit [www.anebulo.com](http://www.anebulo.com).

#### Forward-Looking Statements

This press release contains forward-looking statements as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements, along with terms such as “anticipate,” “expect,” “intend,” “may,” “will,” “should” and other comparable terms, involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Those statements include statements regarding the intent, belief or current expectations of Anebulo Pharmaceuticals and members of its management, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, including risks attendant to developing, testing and commercializing the company’s product candidates, and those described in Anebulo Pharmaceutical’s most recent annual report on Form 10-K and in other periodic reports filed with the SEC, and that actual results may differ materially from those contemplated by such forward-looking statements. Except as required by federal securities law, Anebulo Pharmaceuticals undertakes no obligation to update or revise forward-looking statements to reflect changed conditions.

#### CONTACTS:

##### Anebulo Pharmaceuticals, Inc.

Scott Anderson  
Head of Investor Relations and Public Relations  
(858) 229-7063  
[scott@anebulo.com](mailto:scott@anebulo.com)

Rex Merchant  
Chief Financial Officer  
(512) 598-0931  
[IR@anebulo.com](mailto:IR@anebulo.com)

**Anebulo Pharmaceuticals, Inc.  
Condensed Balance Sheet Data**

**March 31, 2022**

**June 30, 2021**

**Assets**

Cash	\$	16,547,727	\$	19,985,645
Total assets	\$	<u>17,248,467</u>	\$	<u>21,653,491</u>
<b>Liabilities and stockholders' equity</b>				
Total liabilities		85,777		241,633
Total stockholders' equity		<u>17,162,690</u>		<u>21,411,858</u>
Total liabilities and stockholders' equity	\$	<u>17,248,467</u>	\$	<u>21,653,491</u>

**Anebulo Pharmaceuticals, Inc.**  
**Condensed Statements of Operations**

	Three Months Ended March 31,	
	2022	2021
Research and development	\$ 915,363	\$ 273,038
General and administrative	964,281	279,093
Total operating expenses	<u>1,879,644</u>	<u>552,131</u>
Loss from operations	(1,879,644)	(552,131)
Other income (expenses), net	3,153	(3,701)
Net loss	\$ (1,876,491)	\$ (555,832)
Deemed dividends	-	(8,208,393)
Net loss attributable to common stockholders	<u>(1,876,491)</u>	<u>(8,764,225)</u>
Weighted average common shares outstanding, basic and diluted	<u>23,344,567</u>	<u>12,982,500</u>
Net loss per share, basic and diluted	\$ (0.08)	\$ (0.68)

# # #